SCHOTT Pharma Reports Resilient First Half and Strong Cash Flow

SCHOTT Pharma AG & Co. KGaA announced robust financial performance for the first half of the fiscal year 2026, with revenues reaching €488.1 million, a 2.3% increase on a currency-adjusted basis. The EBITDA margin remained stable at 26.6%, compared to 27.0% in the previous year. High Value Solutions made up 56% of total revenue, reflecting the company's strategic focus.

The company reported a more than doubled free cash flow, reaching €45.4 million, bolstered by improved receivables management. Growth was driven mainly by the Drug Containment Solutions segment, which saw an 8.3% increase in currency-adjusted revenue. However, the Drug Delivery Systems segment experienced a 5.4% decline, attributed to reduced demand for polymer syringes.

SCHOTT Pharma continues to invest in expanding its capacity, particularly in Switzerland and Hungary, while confirming its annual forecast of 2-5% revenue growth and an EBITDA margin of around 27% for 2026.